Enovis (NYSE:ENOV – Get Free Report) and CeriBell (NASDAQ:CBLL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Profitability
This table compares Enovis and CeriBell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -22.86% | 13.23% | 5.19% |
| CeriBell | -67.96% | -52.59% | -40.92% |
Volatility and Risk
Enovis has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, CeriBell has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 1 | 1 | 10 | 0 | 2.75 |
| CeriBell | 1 | 1 | 3 | 1 | 2.67 |
Enovis presently has a consensus price target of $38.62, suggesting a potential upside of 39.22%. CeriBell has a consensus price target of $31.25, suggesting a potential upside of 19.55%. Given Enovis’ stronger consensus rating and higher probable upside, research analysts plainly believe Enovis is more favorable than CeriBell.
Institutional & Insider Ownership
98.5% of Enovis shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 17.7% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Enovis and CeriBell”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.25 billion | 0.71 | -$1.18 billion | ($9.21) | -3.01 |
| CeriBell | $89.06 million | 11.40 | -$53.41 million | ($1.94) | -13.47 |
CeriBell has lower revenue, but higher earnings than Enovis. CeriBell is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Summary
Enovis beats CeriBell on 10 of the 15 factors compared between the two stocks.
About Enovis
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
About CeriBell
Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
